Motexafin lutetium clinical trials
Also written PCI-0123 and lutetium texaphyrin.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How each study uses motexafin lutetium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2000 (2)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2004 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses motexafin lutetium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial NeoplasiaTerminatedPhase 1National Cancer Institute (NCI)NCT00005808Written as motexafin lutetium
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNot applicableNational Cancer Institute (NCI)NCT00087191Written as motexafin lutetium
- Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate CancerTerminatedPhase 1National Cancer Institute (NCI)NCT00005067Written as motexafin lutetium
Codes
What other systems call motexafin lutetium · ClinicalTrials.gg INT003946
- MeSH (NLM) C102825motexafin lutetiumConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0A85BJ22L6MOTEXAFIN LUTETIUMConfirmed FDA, NLM
- NCI Thesaurus C1651Motexafin LutetiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C102825 | motexafin lutetium | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0A85BJ22L6 | MOTEXAFIN LUTETIUM | Confirmed FDA, NLM |
| NCI Thesaurus | C1651 | Motexafin Lutetium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.